JLPC(SH:600513) Sou Hu Cai Jing·2025-10-24 14:02Core Insights - Lianhuan Pharmaceutical (600513) reported a revenue of 2.08 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 26.6% [1] - The company experienced a net loss attributable to shareholders of 35.06 million yuan, a decline of 137.8% compared to the previous year [1] - The net profit excluding non-recurring items was 22.30 million yuan, down 75.3% year-on-year [1] Financial Performance - For Q3 2025, the company achieved a revenue of 797 million yuan, reflecting a year-on-year increase of 53.8% [1] - The net profit attributable to shareholders for Q3 was 497,000 yuan, a decrease of 83.3% year-on-year [1] - The net profit excluding non-recurring items for Q3 was 279,000 yuan, down 90.5% year-on-year [1] Cash Flow and Assets - The net cash flow from operating activities was -173 million yuan for the first three quarters, a decline of 819.0% year-on-year [1] - As of the end of Q3, total assets amounted to 4.109 billion yuan, an increase of 36.1% compared to the end of the previous year [1] - The net assets attributable to shareholders were 1.335 billion yuan, a decrease of 4.3% from the end of the previous year [1] Industry Context - Lianhuan Pharmaceutical operates in the pharmaceutical manufacturing industry, integrating research and development, production, and sales [1] - The decline in net profit is attributed to reduced sales gross margin due to centralized procurement and medical insurance payments [1]